FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:2016-2018 June 28, 2001 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Ridker, P. M. PubMed Citation

C-reactive protein is the classic acute-phase reactant. During severe infection or inflammation, blood concentrations of C-reactive protein may increase by a factor of 500 or more. Although most other acute-phase reactants are not as dynamic or as easily measured, they and C-reactive protein may make important contributions to the body's responses to injury, infection, and other sources of stress.

Many acute-phase proteins are thought to be antiinfective. C-reactive protein binds to phosphocholine on the surfaces of invading microbes and marks them for killing by complement and phagocytes, whereas secretory phospholipase A₂ is a potent antistaphylococcal and antistreptococcal enzyme. Acute-phase proteins . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Keddissi, J. I., Younis, W. G., Chbeir, E. A., Daher, N. N., Dernaika, T. A., Kinasewitz, G. T. (2007). The Use of Statins and Lung Function in Current and Former Smokers. Chest 132: 1764-1771 [Abstract] [Full Text]  
• Schifferli, J. A., Goldberg, R. B., Mendez, A. J., Murali, M. R. (2007). Case 40-2006: Anemia and Low HDL Cholesterol. NEJM 356: 1893-1895 [Full Text]  
• Suzuki, M., Saito, M., Nagai, T., Saeki, H., Kazatani, Y. (2006). Systemic Versus Coronary Levels of Inflammation in Acute Coronary Syndromes. ANGIOLOGY 57: 459-463 [Abstract]  
• Da Silva, J A P, Jacobs, J W G, Kirwan, J R, Boers, M, Saag, K G, Ines, L B S, de Koning, E J P, Buttgereit, F, Cutolo, M, Capell, H, Rau, R, Bijlsma, J W J (2006). Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 65: 285-293 [Abstract] [Full Text]  
• Meuwissen, M, van der Wal, A C, Niessen, H W M, Koch, K T, de Winter, R J, van der Loos, C M, Rittersma, S Z H, Chamuleau, S A J, Tijssen, J G P, Becker, A E, Piek, J J (2006). Colocalisation of intraplaque C reactive protein, complement, oxidised low density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction. J. Clin. Pathol. 59: 196-201 [Abstract] [Full Text]  
• Fuster, V., Moreno, P. R., Fayad, Z. A., Corti, R., Badimon, J. J. (2005). Atherothrombosis and High-Risk Plaque: Part I: Evolving Concepts. J Am Coll Cardiol 46: 937-954 [Abstract] [Full Text]  
• Dong, J., Fujii, S., Li, H., Nakabayashi, H., Sakai, M., Nishi, S., Goto, D., Furumoto, T., Imagawa, S., Zaman, T. A.K.M., Kitabatake, A. (2005). Interleukin-6 and Mevastatin Regulate Plasminogen Activator Inhibitor-1 Through CCAAT/Enhancer-Binding Protein-{delta}. Arterioscler. Thromb. Vasc. Bio. 25: 1078-1084 [Abstract] [Full Text]  
• MacCallum, P. K. (2005). Markers of Hemostasis and Systemic Inflammation in Heart Disease and Atherosclerosis in Smokers. Proc Am Thorac Soc 2: 34-43 [Abstract] [Full Text]  
• Pleiner, J., Schaller, G., Mittermayer, F., Zorn, S., Marsik, C., Polterauer, S., Kapiotis, S., Wolzt, M. (2004). Simvastatin Prevents Vascular Hyporeactivity During Inflammation. Circulation 110: 3349-3354 [Abstract] [Full Text]  
• Amarenco, P., Tonkin, A. M. (2004). Statins for Stroke Prevention: Disappointment and Hope. Circulation 109: III-44-III-49 [Abstract] [Full Text]  
• Pickup, J. C. (2004). Inflammation and Activated Innate Immunity in the Pathogenesis of Type 2 Diabetes. Diabetes Care 27: 813-823 [Abstract] [Full Text]  
• Backes, J. M, Howard, P. A, Moriarty, P. M (2004). Role of C-Reactive Protein in Cardiovascular Disease. The Annals of Pharmacotherapy 38: 110-118 [Abstract] [Full Text]  
• Bell, A., Gagnon, A., Sorisky, A. (2003). TSH Stimulates IL-6 Secretion from Adipocytes in Culture. Arterioscler. Thromb. Vasc. Bio. 23: e65-e65 [Full Text]  
• Hirschfield, G.M., Pepys, M.B. (2003). C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM 96: 793-807 [Abstract] [Full Text]  
• Girndt, M., Kohler, H. (2003). Interleukin-10 (IL-10): an update on its relevance for cardiovascular risk. Nephrol Dial Transplant 18: 1976-1979 [Full Text]  
• Almog, Y. (2003). Statins, Inflammation, and Sepsis: Hypothesis. Chest 124: 740-743 [Abstract] [Full Text]  
• Shishehbor, M. H., Brennan, M.-L., Aviles, R. J., Fu, X., Penn, M. S., Sprecher, D. L., Hazen, S. L. (2003). Statins Promote Potent Systemic Antioxidant Effects Through Specific Inflammatory Pathways. Circulation 108: 426-431 [Abstract] [Full Text]  
• Schattner, A., Liang, M. H. (2003). The Cardiovascular Burden of Lupus: A Complex Challenge. Arch Intern Med 163: 1507-1510 [Full Text]  
• Tiemeier, H., van Tuijl, H R., Hofman, A., Kiliaan, A. J, Breteler, M. M. (2003). Plasma fatty acid composition and depression are associated in the elderly: the Rotterdam Study. Am. J. Clin. Nutr. 78: 40-46 [Abstract] [Full Text]  
• Fernandez-Real, J. M., Ricart, W. (2003). Insulin Resistance and Chronic Cardiovascular Inflammatory Syndrome. Endocr. Rev. 24: 278-301 [Abstract] [Full Text]  
• Johnson, B. A., Iacono, A. T., Zeevi, A., McCurry, K. R., Duncan, S. R. (2003). Statin Use Is Associated with Improved Function and Survival of Lung Allografts. Am. J. Respir. Crit. Care Med. 167: 1271-1278 [Abstract] [Full Text]  
• Kitas, G. D., Erb, N. (2003). Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology (Oxford) 42: 607-613 [Full Text]  
• Bonetti, P.O, Lerman, L.O, Napoli, C, Lerman, A (2003). Statin effects beyond lipid lowering--are they clinically relevant?. Eur Heart J 24: 225-248 [Full Text]  
• Engstrom, G., Stavenow, L., Hedblad, B., Lind, P., Eriksson, K.-F., Janzon, L., Lindgarde, F. (2003). Inflammation-Sensitive Plasma Proteins, Diabetes, and Mortality and Incidence of Myocardial Infarction and Stroke: A Population-Based Study. Diabetes 52: 442-447 [Abstract] [Full Text]  
• Sposito, A. C., Chapman, M. J. (2002). Statin Therapy in Acute Coronary Syndromes: Mechanistic Insight Into Clinical Benefit. Arterioscler. Thromb. Vasc. Bio. 22: 1524-1534 [Abstract] [Full Text]  
• Plenge, J. K., Hernandez, T. L., Weil, K. M., Poirier, P., Grunwald, G. K., Marcovina, S. M., Eckel, R. H. (2002). Simvastatin Lowers C-Reactive Protein Within 14 Days: An Effect Independent of Low-Density Lipoprotein Cholesterol Reduction. Circulation 106: 1447-1452 [Abstract] [Full Text]  
• Futterman, L. G., Lemberg, L. (2002). High-Sensitivity C-Reactive Protein Is the Most Effective Prognostic Measurement of Acute Coronary Events. Am J Crit Care 11: 482-486 [Full Text]  
• Engstrom, G., Lind, P., Hedblad, B., Stavenow, L., Janzon, L., Lindgarde, F. (2002). Effects of Cholesterol and Inflammation-Sensitive Plasma Proteins on Incidence of Myocardial Infarction and Stroke in Men. Circulation 105: 2632-2637 [Abstract] [Full Text]  
• Kluft, C. (2002). Is C-reactive protein an additional, surrogate end-point for statin treatment?. Eur Heart J 23: 761-764 [Full Text]  
• Gorelick, P. B. (2002). Stroke Prevention Therapy Beyond Antithrombotics: Unifying Mechanisms in Ischemic Stroke Pathogenesis and Implications for Therapy: An Invited Review. Stroke 33: 862-875 [Abstract] [Full Text]  
• McCullough, P. A., McCarey, D. W., McInnes, I. B., Sattar, N., Ikeda, U., Shimada, K., Ridker, P. M., Gotto, A. M. Jr., Munford, R. S. (2001). The Antiinflammatory Effects of Statins. NEJM 345: 1209-1211 [Full Text]